Currently a patient receiving angioplasty is more likely to die from non-cardiac causes

Original title: Trends in cause of death after percutaneous coronary intervention. Reference: Spoon DB et al. Circulation. 2014; Epub ahead of print.

 

This retrospective study evaluated the specific cause of death in 19077patients who received angioplasty in a center between 1991 and 2008. To perform the analysis, the track was divided into three time periods: 1991-1996, 1997-2002, and 2003-2008. From all patients included, 6998 died at following up (37%, 4.48/100 patient-year) within which could determine the specific cause of death in 6857 (98.1 %). Cardiac mortality recorded for the period 1991-1996 was 9.8 %, decreasing to 7.4 % for 1997-2002 and finally 6.6 % for the last period, which means a 33% decrease in cardiac death within 5 years angioplasty index. Concomitantly, an increase of 57 % in the death of noncardiac causes (7.1 %, 8.5 % and 11.2 % respectively) was observed. Currently only 36.8% of patients receiving angioplasty die from cardiac causes, showing a similar trend in the different subgroups as elderly , magnitude of coronary disease and an indication for angioplasty (chronic angina or acute coronary syndrome). After adjusting all baseline variables, a decrease of 50 % in cardiac mortality over the years and a similar rate of non-cardiac deaths were observed. The decrease in cardiac death was due to a lower rate of fatal heart attacks and sudden death       (p < 0.001) but not heart failure deaths (p = 0.85). The increase in non- cardiac deaths was mainly due to cancer and other chronic diseases (p < 0.001).

Conclusion

This work showed a marked change in the last two decades regarding the cause of death in patients who received angioplasty (mainly cardiac to mainly non-cardiac). The reduction in cardiac death was independent of changes in baseline characteristics observed in the same period of time.

Editorial comment

The time periods for the division were chosen to correspond approximately to changes in the way angioplasties were performed: balloon angioplasty and provisional stenting in 1991-1996, routine angioplasty with conventional stent in 1997-2002 and conventional angioplasty with pharmacological stent 2003-2008. It is noteworthy that a death by heart failure has remained stable over time despite all pharmacological and devices advances.

SOLACI.ORG

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....